Development of a laser-driven proton accelerator for cancer therapy

C. M. Ma, I. Veltchev, E. Fourkal, J. S. Li, W. Luo, J. Fan, T. Lin, A. Pollack

Research output: Contribution to journalArticlepeer-review

69 Scopus citations

Abstract

Recent advances in laser technology have made proton (light ion) acceleration possible using laser-induced plasmas. In this work, we report our work for the last few years on the investigation of a new proton therapy system for radiation oncology, which employs laser-accelerated protons. If successfully developed, the new system will be compact, cost-effective, and capable of delivering energy-and intensity-modulated proton therapy (EIMPT). We have focused our research on three major aspects: (1) target design for laser-proton acceleration, (2) system design for particle/energy selection and beam collimation, and (3) dosimetric studies on the use of laser-accelerated protons for cancer therapy. We have performed particle-in-cell (PIC) simulations to investigate optimal target configurations for proton/ion acceleration. We also performed Monte Carlo simulations to study the beam characteristics and the feasibility of using such beams for cancer treatment. Since laser-accelerated protons have broad energy and angular distributions, which are not suitable for radiotherapy applications directly, we have designed a compact particle selection and beam collimating system for EIMPT beam delivery. We also proposed a new gantry design to make the whole system compact to retrofit existing linac vaults. We have compared Monte Carlo calculated dose distributions using X-ray IMRT and laser-proton EIMPT. Our results show that EIMPT using laser protons produces superior target coverage and much reduced critical structure dose and integral dose compared to X-ray IMRT.

Original languageEnglish
Pages (from-to)639-646
Number of pages8
JournalLaser Physics
Volume16
Issue number4
DOIs
StatePublished - Apr 2006

Fingerprint

Dive into the research topics of 'Development of a laser-driven proton accelerator for cancer therapy'. Together they form a unique fingerprint.

Cite this